APGE Insider Trading Activity and SEC Form 4 Filings
APGE insider trading summary
Over the past 12 months, insiders at Apogee Therapeutics, Inc. (APGE) reported 75 sales worth $571.1M by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $571.1M.
Latest APGE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 5, 2026 | Carl Dambkowski | Chief Medical Officer | Sell | $738K (5,500 @ $134.17) |
| Jul 8, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sell | $2.7M (20,000 @ $133.63) |
| Jun 22, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sell | $10.6M (80,000 @ $132.54) |
| Jun 22, 2026 | Carl Dambkowski | Chief Medical Officer | Sell | $3.5M (26,400 @ $132.60) |
| Jun 10, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sell | $634K (7,654 @ $82.78) |
| Jun 10, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sell | $557K (6,770 @ $82.21) |
| Jun 10, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sell | $134K (1,577 @ $85.19) |
| Jun 10, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sell | $53K (614 @ $86.89) |
| Jun 10, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sell | $91K (1,080 @ $84.18) |
| Jun 10, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sell | $199K (2,305 @ $86.27) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.